Conference Speakers

Dr. Jubin has over 30 years’ experience in the pharmaceutical/biotech industries. His current role at Prolong is leading the advanced translational research and clinical development of SANGUINATE® (PEGylated carboxyhemoglobin bovine, a.k.a.,PP-007) . The investigational drug product is currently being evaluated in a multi-center US clinical trial of safety and efficacy in acute ischemic stroke. The “Blood is not an option” (BNAO) hemorrhagic/hypovolemic shock study is another example of an acute injury/treatment completed clinical trial. PP-007 has also been studied in chronic disease conditions including multiple phI/phII clinical trials in sickle cell anemia where the oxygen transfer properties were elegantly displayed through visualized RBC unsickling across both non-clinical and clinical studies.

These study data will be reported at the19th International Symposium on Blood Substitutes.

Previously, Dr. Jubin’s research experience has included the discovery characterization of dozens of interferon genes across multiple species, the RNA crystal structure determination of the hepatitis C virus (HCV) internal ribosome entry site as well as the development and global regulatory approvals of the first-line HCV-directed therapies including Interferon-alpha2b (IntronA®), PEGylated interferon-alpha2b (PEG-INTRON®) in combination with Ribavirin (REBETOL®) and the HCV protease inhibitor (Boceprevir) Victrelis®.

Dr. Jubin received his Ph.D. in Microbiology & Molecular Genetics from Rutgers Medical School Newark, NJ (previously UMDNJ), his M.S. degree in Microbiology from Seton hall University and a B.A. in Biology from Kean University. Dr. Jubin has also taught and mentored as an adjunct Professor of Biology at both Seton Hall and Kean Universities graduate and undergraduate programs for over 10 years combined.